GTSM:4174

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OBI Pharma, Inc., a bio-pharma company, develops and licenses therapeutic agents for unmet medical needs against cancer in Taiwan. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has OBI Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4174 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 4174's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-5.0%

4174

-2.3%

TW Biotechs

-0.2%

TW Market


1 Year Return

-13.7%

4174

21.7%

TW Biotechs

28.6%

TW Market

Return vs Industry: 4174 underperformed the TW Biotechs industry which returned 21.7% over the past year.

Return vs Market: 4174 underperformed the TW Market which returned 28.6% over the past year.


Shareholder returns

4174IndustryMarket
7 Day-5.0%-2.3%-0.2%
30 Day-20.1%-7.8%8.8%
90 Day0%-2.8%20.6%
1 Year-13.7%-13.7%22.2%21.7%33.1%28.6%
3 Year-37.3%-37.3%-17.7%-19.2%55.3%37.8%
5 Year-81.1%-81.1%-48.1%-48.6%135.7%94.2%

Long-Term Price Volatility Vs. Market

How volatile is OBI Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OBI Pharma undervalued compared to its fair value and its price relative to the market?

5.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4174's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4174's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4174 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4174 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4174's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4174 is overvalued based on its PB Ratio (5.1x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is OBI Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OBI Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has OBI Pharma performed over the past 5 years?

-9.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4174 is currently unprofitable.

Growing Profit Margin: 4174 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4174 is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.

Accelerating Growth: Unable to compare 4174's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4174 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 4174 has a negative Return on Equity (-33.99%), as it is currently unprofitable.


Next Steps

Financial Health

How is OBI Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 4174's short term assets (NT$4.0B) exceed its short term liabilities (NT$176.7M).

Long Term Liabilities: 4174's short term assets (NT$4.0B) exceed its long term liabilities (NT$169.8M).


Debt to Equity History and Analysis

Debt Level: 4174's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 4174's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4174 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4174 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 14.8% each year.


Next Steps

Dividend

What is OBI Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4174's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4174's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4174's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4174's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4174's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Michael N. Chang (70 yo)

1.42yrs

Tenure

NT$2,563,000

Compensation

Dr. Michael N. Chang, Ph.D., serves as Partner at Delos Advisors Limited. He served as Consultant of Optimer Pharmaceuticals, Inc. since May 2010. Dr. Chang co-founded Optimer Pharmaceuticals, Inc. in Nove...


Leadership Team

NamePositionTenureCompensationOwnership
Michael N. Chang
CEO & Chairman1.42yrsNT$2.56mno data
Chi-Chuan Chen
CFO & Director4.58yrsNT$55.00kno data
Ming-Tain Lai
Chief Scientific Officer1.33yrsno datano data
Sharon Lee
Director of Public Relations & Government Affairs Division4.83yrsno datano data
Cheng-Der Yu
Chief Medical Advisor0.83yrno datano data
Kevin P. Poulos
Chief Commercial Officer of USA8yrsno datano data
Tillman Elder Pearce
Chief Medical Officer1.25yrsno datano data
Mitchell Che
Chief Operating Officer of USA7.33yrsno datano data
Xiu-Mei Huang
Chief Executive Officer of OBI Pharma (Shanghai) Limited1.17yrsno datano data

1.4yrs

Average Tenure

62.5yo

Average Age

Experienced Management: 4174's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael N. Chang
CEO & Chairman1.42yrsNT$2.56mno data
Chi-Chuan Chen
CFO & Director4.58yrsNT$55.00kno data
Yun Yen
Directorno datano datano data
Tamon Tseng
Director7.92yrsNT$45.00kno data
Jerry G. Fong
Independent Director6.5yrsNT$700.00kno data
Wang Taychang
Independent Director4.58yrsNT$700.00kno data

4.6yrs

Average Tenure

65yo

Average Age

Experienced Board: 4174's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

OBI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OBI Pharma, Inc.
  • Ticker: 4174
  • Exchange: GTSM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$21.405b
  • Shares outstanding: 188.59m
  • Website: https://www.obipharma.com

Location

  • OBI Pharma, Inc.
  • No. 3, Park Street
  • Room 1907, 19th Floor
  • Taipei
  • 115
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4174GTSM (Taipei Exchange)YesCommon StockTWTWDDec 2012

Biography

OBI Pharma, Inc., a bio-pharma company, develops and licenses therapeutic agents for unmet medical needs against cancer in Taiwan. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 17:31
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.